GMAB – Genmab A/S

GMAB — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.45

Margin Of Safety %

Put/Call OI Ratio

0.11

EPS Next Q Diff

0.16

EPS Last/This Y

-0.51

EPS This/Next Y

0.79

Price

26.01

Target Price

37.21

Analyst Recom

1.39

Performance Q

0.77

Upside

78.9%

Beta

0.84

Ticker: GMAB

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	GMAB	23.86	0.10	0.03	66678
2026-06-03	GMAB	23.88	0.09	7.33	69208
2026-06-04	GMAB	24.73	0.09	2.75	69364
2026-06-05	GMAB	25.16	0.10	0.00	69684
2026-06-08	GMAB	24.8	0.10	0.03	69701
2026-06-09	GMAB	25.1	0.10	0.03	70305
2026-06-10	GMAB	24.47	0.10	0.29	70640
2026-06-11	GMAB	25.24	0.10	7.40	70643
2026-06-12	GMAB	25.08	0.11	0.07	70993
2026-06-15	GMAB	24.57	0.11	0.10	70993
2026-06-16	GMAB	24.75	0.10	0.36	70810
2026-06-17	GMAB	25.39	0.10	0.22	70849
2026-06-18	GMAB	25.26	0.10	0.01	70872
2026-06-22	GMAB	25.6	0.09	0.77	67862
2026-06-23	GMAB	25.93	0.10	0.00	68260
2026-06-24	GMAB	25.86	0.11	0.16	64880
2026-06-25	GMAB	26.12	0.11	0.00	65530
2026-06-26	GMAB	26.11	0.11	0.00	63826
2026-06-29	GMAB	26.01	0.11	0.38	64328
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	GMAB	25.45	-	-24.5	1.04
2026-06-02	GMAB	23.86	-	-52.4	1.04
2026-06-03	GMAB	23.88	-	9.5	1.04
2026-06-04	GMAB	24.73	-	42.3	1.04
2026-06-05	GMAB	25.16	-	24.2	1.04
2026-06-08	GMAB	24.79	-	10.4	1.04
2026-06-09	GMAB	25.10	-	-7.0	1.04
2026-06-10	GMAB	24.48	-	1.0	1.04
2026-06-11	GMAB	25.23	-	20.1	1.04
2026-06-12	GMAB	25.08	-	31.3	1.04
2026-06-15	GMAB	24.58	-	11.7	1.04
2026-06-16	GMAB	24.75	-	15.0	1.04
2026-06-17	GMAB	25.39	-	64.8	1.04
2026-06-18	GMAB	25.26	-	-14.4	1.04
2026-06-22	GMAB	25.61	-	3.2	1.04
2026-06-23	GMAB	25.94	-	-0.7	1.04
2026-06-24	GMAB	25.86	-	-33.3	1.04
2026-06-25	GMAB	26.13	-	-21.0	1.04
2026-06-26	GMAB	26.11	-	-30.5	1.04
2026-06-29	GMAB	26.01	-	1.6	1.04
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	GMAB	0.00	-0.33	1.72
2026-06-03	GMAB	0.00	-0.33	1.72
2026-06-04	GMAB	0.00	-0.33	1.72
2026-06-05	GMAB	0.00	-0.33	1.72
2026-06-08	GMAB	0.00	-0.34	1.72
2026-06-09	GMAB	0.00	-0.34	1.72
2026-06-10	GMAB	0.00	-0.34	1.70
2026-06-11	GMAB	0.00	-0.34	1.70
2026-06-12	GMAB	0.00	-0.34	1.70
2026-06-15	GMAB	0.00	-0.33	1.70
2026-06-16	GMAB	0.00	-0.33	1.70
2026-06-17	GMAB	0.00	-0.33	1.70
2026-06-18	GMAB	0.00	-0.33	1.70
2026-06-22	GMAB	0.00	-0.18	1.70
2026-06-23	GMAB	0.00	-0.18	1.70
2026-06-24	GMAB	0.00	-0.18	1.70
2026-06-25	GMAB	0.00	-0.18	1.70
2026-06-26	GMAB	0.00	-0.18	1.45
2026-06-29	GMAB	0.00	-0.18	1.45
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

0.3

Avg. EPS Est. Next Quarter

0.31

Insider Transactions

Institutional Transactions

-0.18

Beta

0.84

Average Sales Estimate Current Quarter

6985

Average Sales Estimate Next Quarter

7344

Fair Value

27.62

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-63.1

Target Price

37.21

P/E

19.62

Forward P/E

15.3

PEG

0.84

P/S

3.96

P/B

2.81

P/Free Cash Flow

17.69

EPS

1.33

Average EPS Est. Cur. Y

1.04

EPS Next Y. (Est.)

1.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

21.06

Relative Volume

1.13

Return on Equity vs Sector %

-13.2

Return on Equity vs Industry %

3.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

1.6

◆ GMAB Healthcare

$26.02

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

17/25

Volume

4/15

Valuation

18/20

TP/AR

2/10

Options

6/10

RSI

Range 1M

88%

Sup Dist

1.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

13/30

Estimates

6/20

Inst/Vol

4/15

Options

10/10

EPS Yr

-26%

EPS NY

49.4%

52W%

38.5%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +83.5% upside

Quality

15/30

Valuation

22/30

Growth

9/25

Stability

4/10

LT Trend

2/5

Upside

+83.5%

Quality

MoS

GMAB — P/E HistoricalBiotechnology

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 3088

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

GMAB

Latest News

—

Caricamento notizie per GMAB…

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

NVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.73

Margin Of Safety %

-16

Put/Call OI Ratio

0.66

EPS Next Q Diff

3.72

EPS Last/This Y

18.03

EPS This/Next Y

0.03

Price

48.33

Target Price

48.81

Analyst Recom

2.38

Performance Q

34.11

Upside

14.6%

Beta

0.76

Ticker: NVO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	NVO	42.91	0.65	1.10	1422047
2026-06-03	NVO	42	0.64	0.41	1430952
2026-06-04	NVO	43.74	0.64	0.66	1449359
2026-06-05	NVO	42.94	0.64	0.47	1463191
2026-06-08	NVO	41.02	0.64	0.54	1430412
2026-06-09	NVO	42.19	0.63	0.35	1447509
2026-06-10	NVO	42.79	0.63	0.51	1462681
2026-06-11	NVO	43.97	0.64	0.54	1496648
2026-06-12	NVO	43.88	0.64	0.52	1510902
2026-06-15	NVO	43.92	0.64	0.57	1489852
2026-06-16	NVO	43.56	0.63	0.51	1498665
2026-06-17	NVO	43.53	0.63	1.05	1511329
2026-06-18	NVO	43.19	0.62	0.82	1519038
2026-06-22	NVO	45.9	0.64	0.31	1223672
2026-06-23	NVO	47.39	0.63	0.78	1255436
2026-06-24	NVO	47.4	0.65	0.40	1303693
2026-06-25	NVO	47.63	0.65	0.44	1328258
2026-06-26	NVO	48.08	0.65	0.33	1338121
2026-06-29	NVO	48.33	0.66	0.35	1309329
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	NVO	44.05	-13.2	-5579.6	22.33
2026-06-02	NVO	42.94	-13.2	-5428.5	22.33
2026-06-03	NVO	42.01	-13.2	-4911.6	22.33
2026-06-04	NVO	43.76	-13.2	-3749.5	22.33
2026-06-05	NVO	42.92	-13.2	-4751.8	22.33
2026-06-08	NVO	41.01	-12.8	-5736.1	22.32
2026-06-09	NVO	42.19	-12.8	-13078.9	22.32
2026-06-10	NVO	42.81	-12.8	-3030.6	22.32
2026-06-11	NVO	43.97	-12.8	-3462.5	22.32
2026-06-12	NVO	43.89	-12.8	-3460.2	21.52
2026-06-15	NVO	43.92	-12.8	-3764.3	21.52
2026-06-16	NVO	43.56	-12.8	-3809.7	21.52
2026-06-17	NVO	43.52	-12.8	-4657.1	21.52
2026-06-18	NVO	43.21	-12.8	-5117.5	21.52
2026-06-22	NVO	45.90	-12.8	-3652.3	21.62
2026-06-23	NVO	47.42	-12.8	-4323.5	21.54
2026-06-24	NVO	47.40	-12.8	-4937.5	21.54
2026-06-25	NVO	47.61	-12.8	-4853.9	21.54
2026-06-26	NVO	48.03	-12.8	-4631.4	21.54
2026-06-29	NVO	48.33	-12.8	-4662.0	21.54
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	NVO	0	-3.08	0.64
2026-06-03	NVO	0	-3.08	0.64
2026-06-04	NVO	0	-3.08	0.64
2026-06-05	NVO	0	-3.08	0.64
2026-06-08	NVO	0	-3.03	0.64
2026-06-09	NVO	0	-3.03	0.64
2026-06-10	NVO	0	-3.03	0.67
2026-06-11	NVO	0	-3.03	0.67
2026-06-12	NVO	0	-3.03	0.67
2026-06-15	NVO	0	-3.09	0.67
2026-06-16	NVO	0	-3.09	0.67
2026-06-17	NVO	0	-3.09	0.67
2026-06-18	NVO	0	-3.09	0.67
2026-06-22	NVO	0	-3.02	0.67
2026-06-23	NVO	0	-3.02	0.67
2026-06-24	NVO	0	-3.02	0.68
2026-06-25	NVO	0	-3.02	0.68
2026-06-26	NVO	0	-3.02	0.73
2026-06-29	NVO	0	-3.12	0.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.04

Avg. EPS Est. Current Quarter

5.2

Avg. EPS Est. Next Quarter

4.76

Insider Transactions

Institutional Transactions

-3.12

Beta

0.76

Average Sales Estimate Current Quarter

72066

Average Sales Estimate Next Quarter

71496

Fair Value

40.69

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

67.4

Max Drawdown 5-Year %

-74.7

Target Price

48.81

P/E

11.34

Forward P/E

14.67

PEG

P/S

3.19

P/B

6.86

P/Free Cash Flow

25.3

EPS

4.26

Average EPS Est. Cur. Y

21.54

EPS Next Y. (Est.)

21.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.23

Relative Volume

0.53

Return on Equity vs Sector %

32.4

Return on Equity vs Industry %

21.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.67

EBIT Estimation

-4662

◆ NVO Healthcare

$48.33

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

12/20

Pullback

6/25

Volume

11/15

Valuation

10/20

TP/AR

2/10

Options

6/10

RSI

68.5

Range 1M

99.3%

Sup Dist

2.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

11/30

Estimates

8/20

Inst/Vol

3/15

Options

8/10

EPS Yr

-9.4%

EPS NY

-0.1%

52W%

36.4%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +235.4% upside

Quality

30/30

Valuation

19/30

Growth

10/25

Stability

3/10

LT Trend

4/5

Upside

+235.4%

Quality

MoS

-16%

NVO — P/E HistoricalDrug Manufacturers - General

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 67900

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO

Latest News

—

Caricamento notizie per NVO…

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

ASND — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.23

Margin Of Safety %

-42

Put/Call OI Ratio

0.26

EPS Next Q Diff

EPS Last/This Y

15.72

EPS This/Next Y

-2.01

Price

263.67

Target Price

289.64

Analyst Recom

1.1

Performance Q

21.55

Upside

-56.3%

Beta

0.34

Ticker: ASND

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	ASND	216.48	0.97	0.71	9860
2026-06-03	ASND	217.06	0.96	0.16	9937
2026-06-04	ASND	218.76	0.95	0.01	9992
2026-06-05	ASND	210.39	0.49	0.33	15097
2026-06-08	ASND	205.78	0.49	0.21	15104
2026-06-09	ASND	213.14	0.47	7.06	15066
2026-06-10	ASND	209.98	0.49	0.17	15305
2026-06-11	ASND	215.61	0.49	10.05	15319
2026-06-12	ASND	218.54	0.42	0.07	14751
2026-06-15	ASND	223.41	0.42	0.00	14752
2026-06-16	ASND	230.93	0.41	0.31	14813
2026-06-17	ASND	231.15	0.41	6.78	14974
2026-06-18	ASND	230.58	0.36	0.01	14643
2026-06-22	ASND	228.22	0.22	0.06	10389
2026-06-23	ASND	238.5	0.22	0.00	10582
2026-06-24	ASND	237.76	0.42	0.07	6585
2026-06-25	ASND	261.24	0.39	0.15	6916
2026-06-26	ASND	260.75	0.32	0.05	8516
2026-06-29	ASND	263.83	0.26	0.31	11385
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-01	ASND	218.60	-	-	11.44
2026-06-02	ASND	216.81	-	-	11.44
2026-06-03	ASND	216.85	-	-	11.44
2026-06-04	ASND	218.82	-	-	11.44
2026-06-05	ASND	210.29	-	-	11.44
2026-06-08	ASND	205.78	-	-	11.44
2026-06-09	ASND	213.18	-	-	11.44
2026-06-10	ASND	209.77	-	-	11.44
2026-06-11	ASND	215.32	-	-	11.44
2026-06-12	ASND	218.02	-	-	11.44
2026-06-15	ASND	223.50	-	-	11.44
2026-06-16	ASND	231.05	-	-	11.44
2026-06-17	ASND	230.82	-	-	11.44
2026-06-18	ASND	230.78	-	-	11.44
2026-06-22	ASND	228.10	-	-	11.45
2026-06-23	ASND	238.59	-	-	11.45
2026-06-24	ASND	237.95	-	-	11.45
2026-06-25	ASND	261.30	-	-	11.45
2026-06-26	ASND	261.17	-	-	11.45
2026-06-29	ASND	263.67	-	-	11.45
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	ASND	-3.21	-45.97	2.80
2026-06-03	ASND	-3.19	-45.97	2.80
2026-06-04	ASND	-3.19	-45.97	2.80
2026-06-05	ASND	-3.19	-45.97	2.80
2026-06-08	ASND	-3.19	-45.17	2.80
2026-06-09	ASND	-3.19	-45.17	2.80
2026-06-10	ASND	-3.19	-45.17	2.79
2026-06-11	ASND	-3.19	-45.17	2.79
2026-06-12	ASND	-3.19	-45.17	2.79
2026-06-15	ASND	-3.19	-45.14	2.79
2026-06-16	ASND	-3.19	-45.14	2.79
2026-06-17	ASND	-3.19	-45.14	2.79
2026-06-18	ASND	-3.19	-45.14	2.79
2026-06-22	ASND	-3.19	-44.75	2.79
2026-06-23	ASND	-3.19	-44.75	2.79
2026-06-24	ASND	-3.19	-44.75	2.79
2026-06-25	ASND	-3.19	-44.75	2.79
2026-06-26	ASND	-3.19	-44.75	3.23
2026-06-29	ASND	-3.19	-44.74	3.23
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.7

Avg. EPS Est. Next Quarter

1.15

Insider Transactions

-3.19

Institutional Transactions

-44.74

Beta

0.34

Average Sales Estimate Current Quarter

331

Average Sales Estimate Next Quarter

354

Fair Value

153.6

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

289.64

P/E

29.72

Forward P/E

24.56

PEG

P/S

16.29

P/B

29.13

P/Free Cash Flow

323.88

EPS

8.87

Average EPS Est. Cur. Y

11.45

EPS Next Y. (Est.)

9.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

57.88

Relative Volume

1.17

Return on Equity vs Sector %

Return on Equity vs Industry %

90.8

EPS 1 7Days Diff

EPS 1 30Days Diff

1.61

EBIT Estimation

◆ ASND Healthcare

$263.70

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

14/20

Pullback

6/25

Volume

4/15

Valuation

5/20

TP/AR

2/10

Options

6/10

RSI

71.7

Range 1M

85.7%

Sup Dist

3.2%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

19/25

Growth

22/30

Estimates

3/20

Inst/Vol

6/15

Options

10/10

EPS Yr

455.5%

EPS NY

-29.5%

52W%

91.2%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🔴 SELL -37.3% upside

Quality

27/30

Valuation

0/30

Growth

14/25

Stability

3/10

LT Trend

4/5

Upside

-37.3%

Quality

MoS

-42%

ASND — P/E HistoricalBiotechnology

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1189

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ASND

Latest News

—

Caricamento notizie per ASND…

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y